Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.

Cécile van SteenLorenzo CelicoErik SpaepenTim Hagenacker Sven Guenther Meuth Tobias Ruck A Gordon Smith Danielle H Bodicoat Maria De Francesco Sergio Iannazzo

Published in: Advances in therapy (2024)

Efgartigimod may provide a faster and greater improvement over 26 weeks in quality of life than ravulizumab in adults with AChR-Ab+ gMG. Efgartigimod showed faster improvements in MG-ADL and QMG than ravulizumab.

Keyphrases

myasthenia gravis
binding protein